- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04821778
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
August 17, 2022 updated by: Wang Xin, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cohort Study of Definitive Chemoradiotherapy for Esophageal or Esophagogastric Junction Cancer
Definitive chemoradiotherapy is the standard of care in unresectable esophageal or esophagogastric cancer.
A multidisciplinary approach, including chemotherapy and radiotherapy, is important for these patients.
Morerover, molecular targeting agents does not show clear efficacy in EC up to now.
Nowadays, the pace of development of cancer immunotherapies is accelerating.
Clinical evidence of the efficacy of immune checkpoint inhibitors and adoptive immunotherapies herald the onset of a new era in cancer immunotherapy.
There have also been recent developments to provide a promising frontier in extending the use of immunotherpay or targeting agents to radiotherapy.
The purpose of this study was to explore the optimal treatment modalities including PD-1/PD-L1 antibody or targeted drug for patients with unresectable esophageal or esophagogastric junction cancer.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
2000
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100021
- Recruiting
- Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
-
Changsha, China
- Recruiting
- Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
-
Contact:
- Qin Xiao
- Email: xiaoqin_200909@163.com
-
Nanjing, China
- Recruiting
- Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University
-
Contact:
- Cheng Chen
-
-
Henan
-
Anyang, Henan, China
- Recruiting
- Department 4th of Radiation Oncology, Anyang Cancer Hospital
-
Contact:
- Yidian Zhao
- Email: ayydz101@163.com
-
Contact:
- Xiaomin Wang
- Email: shine828@163.com
-
-
Jiangsu
-
Nanjing, Jiangsu, China
- Recruiting
- Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University
-
Contact:
- Xiaolin Ge
- Email: doctorgxl@163.com
-
Contact:
- Xinchen Sun
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- ≥18 years;
- Esophageal or Esophagogastric cancer;
- Histologically proven squamous cell carcinoma or adenocarcinoma in patients staged as I-IVa(AJCC 8th);
- Primary treatment performed in Cancer Hospital, Chinese Academy of Medical Sciences;
- ECOG PS score: 0~1;
- Estimated survival time ≥3 months;
- Normal organ and marrow function as defined below:Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal to 4,000 G/L; Neutrophil: greater than or equal to 2,000 G/L; Platelets: greater than or equal to 100,000/mm3 ; Creatinine: less than or equal to 1.5 times the upper limit or CCR greater than or equal to 60 ml/min; AST/ALT: less than or equal to 2.5 times the upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit; INR: less than or equal to 1.5 times the upper limit; APTT: less than or equal to 1.5 times the upper limit; PT: less than or equal to 1.5 times the upper limit;
- Informed consent;
Exclusion Criteria:
- With any distant metastasis out of regional lymphatic drainage or in liver, lung, bone, CNS, etc;
- Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer;
- Existing active infection such as active tuberculosis and hepatitis;
- History of myocardial infarction within the past 6 months or history of ventricular arrhythmia;
- Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness History of allergic reactions attributed to paclitaxel, albumin or cisplatin;
- Participation in other clinical trials currently or within 4 weeks of selection;
- Pregnant or lactating females;
- Absence of medical records.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Definitive Chemoradiation
This arm received chemoradiation without immunotherapy/targeting agents as definitive treatment.
|
50-66Gy/1.8-2.2Gy/25-30f
q1-3W according to physician's preference
q1-3W according to physician's preference
W1-5 qW or d1-14, q3W according to physician's preference
|
Experimental: Chemoradiation Combined With Immunotherapy/targeting agents
This arm received chemoradiation with immunotherapy/targeting agents as definitive treatment.
|
50-66Gy/1.8-2.2Gy/25-30f
q1-3W according to physician's preference
q1-3W according to physician's preference
W1-5 qW or d1-14, q3W according to physician's preference
Anti-PD-1/PD-L1 Antibody
200-400mg, d1,qW
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall survival
Time Frame: 5 year
|
5 year
|
Overall survival
Time Frame: 3 year
|
3 year
|
Overall survival
Time Frame: 2 year
|
2 year
|
Overall survival
Time Frame: 1year
|
1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival
Time Frame: 1 year, 2 year, 3 year, 5 year
|
1 year, 2 year, 3 year, 5 year
|
|
Number of participants with Acute and late toxicities of radiotherapy,chemotherapy and immunotherapy
Time Frame: 3 months
|
3 months
|
|
Pathological response rate
Time Frame: 3 months
|
Pathological response were classified into three grades.Grade
I signifies that there is little shrinkage in the tumor; only mild regression in the tumor cells is observed under themicroscope.
Grade II shows gross reduction in size of the tumor and marked regression in the cancer cells microscopically, yet viable nests of cancer tissue are still visible.
Grade III implies complete or almost total resolution of the tumor on exploration, and disappearance of the tumor tissue microscopically; only remnants of degenerated cancer cells can be seen (so-called ghost cancer cells).
|
3 months
|
R0 resection rate
Time Frame: 3 months
|
3 months
|
|
Locoregional recurrence free survival
Time Frame: 1 year, 2 year, 3 year, 5 year
|
1 year, 2 year, 3 year, 5 year
|
|
Distant metastasis free survival
Time Frame: 1 year, 2 year, 3 year, 5 year
|
1 year, 2 year, 3 year, 5 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analysis of correlation between radiomics signature extracted by LASSO and the number of participants with treatment-related adverse events as assessed by CTCAE v4.0.
Time Frame: 1 year, 2 year, 3 year, 5 year
|
1 year, 2 year, 3 year, 5 year
|
|
Radiomics analysis
Time Frame: 1 year, 2 year, 3 year, 5 year
|
Analysis of correlation between radiomics signature extracted by LASSO and the rate of participants who achieve pathological complete response (pCR) and the overall survival based on MRI and CT simulation.
|
1 year, 2 year, 3 year, 5 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2002
Primary Completion (Anticipated)
December 31, 2025
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
March 15, 2021
First Submitted That Met QC Criteria
March 26, 2021
First Posted (Actual)
March 30, 2021
Study Record Updates
Last Update Posted (Actual)
August 22, 2022
Last Update Submitted That Met QC Criteria
August 17, 2022
Last Verified
August 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Esophageal Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Paclitaxel
- Nimotuzumab
Other Study ID Numbers
- NCC2722
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemoradiation
-
University of KentuckyTerminatedCancer | Chemoradiation
-
Duke UniversityTerminatedPathologically Proven Gastrointestinal Malignancy | Plan of Care Must Include ChemoradiationUnited States
-
Cancer Institute and Hospital, Chinese Academy...UnknownGastric Cancer | ChemoradiationChina
-
Kagawa UniversityCompletedGastric Cancer | ChemoradiationJapan
-
The Netherlands Cancer InstituteCompleted
-
Peking Union Medical College HospitalGeneplus-Beijing Co. Ltd.UnknownRectal Cancer, Adenocarcinoma | Neoadjuvant Chemoradiation
-
Zhejiang Cancer HospitalCompletedEsophageal Cancer | ChemoradiationChina
-
Seoul National University HospitalNational Cancer Center, Korea; Seoul National University Bundang HospitalCompletedChemoradiation | Rectal CancerKorea, Republic of
-
University Medical Center GroningenRecruitingEsophageal Cancer | Chemoradiation | OrganoidNetherlands
-
Ludwig-Maximilians - University of MunichRecruitingQuality of Life | Esophageal Cancer | ChemoradiationGermany
Clinical Trials on Radiotherapy
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
University Hospital OstravaRecruiting
-
IRCCS San RaffaeleRecruitingGynecologic Cancer | Radiotherapy Side Effect | Survivorship | Radiotherapy; Complications | Progression, Disease | Progression, ClinicalItaly
-
Changhai HospitalRecruiting
-
UNC Lineberger Comprehensive Cancer CenterNot yet recruitingHead and Neck Cancer | Xerostomia | Oropharynx CancerUnited States
-
Xiangyun ZongActive, not recruitingQuality of LifeChina
-
Cancer Institute and Hospital, Chinese Academy...Completed
-
Fudan UniversityZhejiang Cancer Hospital; Huashan Hospital; Henan Cancer Hospital; Hunan Cancer... and other collaboratorsNot yet recruiting
-
The Netherlands Cancer InstituteLeiden University Medical CenterRecruitingSoft Tissue SarcomasNetherlands